<DOC>
	<DOCNO>NCT02915224</DOCNO>
	<brief_summary>This multicenter , single arm , non-interventional , observational study evaluate efficacy safety obinutuzumab daily clinical practice participant chronic lymphocytic leukemia ( CLL ) . The study also assess cost disease management . The total length study 42 month .</brief_summary>
	<brief_title>A Study Obinutuzumab Evaluating Efficacy , Safety Cost Disease Management Participants With Chronic Lymphocytic Leukemia Comorbidities</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Participants untreated CLL comorbidities , physician already decide use obinutuzumab association chlorambucil Participation another clinical trial study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>